Clinical diagnosis

Clinical diagnosis of suspected hypersensitivity to abacavir remains the basis for clinical decision making

  • HLA-B*5701 screening for risk of abacavir hypersensitivity should never be substituted for appropriate clinical vigilance and patient management in individuals receiving abacavir
  • HLA-B*5701 testing must not be used as a diagnostic test after a patient has started treatment with abacavir